Amgen, Inc. vs Cassava Sciences Inc — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Amgen, Inc. is far larger — about 4694× Cassava Sciences Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| AMGN | FLNA | |
|---|---|---|
Market Cap | $224.14B | $47.75M |
Sector | Health | Health |
52-Week High | $417.20 | $4.64 |
52-Week Low | $271.18 | $0.87 |
Enterprise Value | $267.45B | -$34.93M |
Dividend Yield | 2.43% | — |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →